ArticleCancer cell2022
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 59 citations in OpenAlex.
- Spatiotemporal dynamics of adoptively transferred stem-like CD8bioRxiv : the preprint server for biology · 2026Article
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- Tissue-resident exhausted and memory CD8Nature immunology · 2026Article
- Light Metabolically Reprograms CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Davanat-Mimetic Galactomannan and Its Sulfated Derivative: Structure and Antitumor Effects against Melanoma.Biomacromolecules · 2025Article
- Immunometabolism: The role of gut-derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy.Clinical and translational medicine · 2025Review
- A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.BMC gastroenterology · 2025Article
- Review
- Divergent ontogeny of Tissue Resident Memory and Tissue Resident Exhausted CD8bioRxiv : the preprint server for biology · 2025Article
- PD-1 is requisite for skin TNature immunology · 2025Article
- Lymph-node-derived stem-like but not tumor-tissue-resident CD8Nature immunology · 2025Article
- Epidermal Resident Memory T Cell Fitness Requires Antigen Encounter in the Skin.bioRxiv : the preprint server for biology · 2025Article
- Article
- Dynamic evolution and antitumor mechanisms of CXCR6Journal of translational medicine · 2025Article
- Article
- Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors.Molecular cancer · 2025Review
- HBV-associated hepatocellular carcinomas inhibit antitumor CD8Nature communications · 2025Article
- The neutrophil-to-lymphocyte ratio and the prevalence of cutaneous melanoma: a retrospective observational study of NHANES statistics spanning 1999 to 2018.Archives of dermatological research · 2025Observational
- Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 12 institutions in 3 countries.
Abhinav JaiswalDepartment of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, NY 10026, USA.
Akanksha VermaInstitute for Computational Biomedicine, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Ruth DannenfelserDepartment of Computer Science and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08540, USA.
Marit MelssenDivision of Surgical Oncology - Breast and Melanoma Surgery, Department of Surgery, Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA 22908, USA; Carter Immunology Center, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Benjamin IzarDepartment of Medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia Center for Translational Immunology and Program for Mathematical Genomics, Columbia University, New York, NY 10032, USA.
Tae-Gyun KimDepartment of Microbiology and Immunology, Yonsei University College of Medicine, Seoul, South Korea.
Christopher J NirschlDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
K Sanjana P DeviDepartment of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA.
Walter C OlsonDivision of Surgical Oncology - Breast and Melanoma Surgery, Department of Surgery, Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA 22908, USA.
Craig L SlingluffDivision of Surgical Oncology - Breast and Melanoma Surgery, Department of Surgery, Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA 22908, USA; Carter Immunology Center, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Victor H EngelhardCarter Immunology Center, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Levi GarrawayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02115, USA; Center for Cancer for Cancer Precision Medicine, Boston, MA 02115, USA; Brigham and Women's Hospital, Boston, MA 02115, USA.
Aviv RegevBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kira MinkisDepartment of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA.
Charles H YoonBrigham and Women's Hospital, Department of Surgical Oncology Harvard Medical School, Boston, MA 02115, USA.
Olga TroyanskayaDepartment of Computer Science and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08540, USA; Simons Center for Data Analysis, Simons Foundation, New York, NY 10010, USA.
Olivier ElementoInstitute for Computational Biomedicine, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Mayte Suárez-FariñasDepartment of Genetics and Genomic Science, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Niroshana AnandasabapathyDepartment of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, NY 10026, USA; Institute for Computational Biomedicine, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10026, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10026, USA. Electronic address: nia9069@med.cornell.edu.
Cornell University · USUniversity of Virginia · USBrigham and Women's Hospital · USBroad Institute · USCarter Center · USColumbia University · USDana-Farber Cancer Institute · USIcahn School of Medicine at Mount Sinai · USPrinceton University · USSimons Foundation · USWeizmann Institute of Science · ILYonsei University · KR
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MDERMATOLOGY TRAINING GRANTT32AR007098 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI THOMAS S. KUPPER · 1986 to 2026
$8.1MInterrogating unique DC adaptations to tissue to promote barrier immunity and toleranceR01AR080436 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Niroshana Anandasabapathy · 2022 to 2026
$3.5MPeripheral mechanisms of homeostasis and tolerance through skin dendritic cellsR01AR070234 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANANDASABAPATHY, NIROSHANA · 2016 to 2020
$2.6MMechanisms of liver metastasis and associated resistance to immunotherapyR37CA258829 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar · 2021 to 2026
$2.6MDissecting mechanisms of immunotherapy resistance in melanoma patientsK08CA222663 · NCI · DANA-FARBER CANCER INST · PI IZAR, BENJAMIN · 2017 to 2021
$827kPeripheral immune surveillance and long-lived barrier immunity through T cell DC cross-talkR56AR078686 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANANDASABAPATHY, NIROSHANA · 2021 to 2021
$649kDissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.R21CA263381 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IZAR, BENJAMIN · 2021 to 2022
$412kFluorescence molecular tomography to study T cell infiltration into tumorsR21CA185955 · NCI · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H, KELLY, KIMBERLY A. · 2014 to 2015
$372kNCI NIH HHS K08 CA222663NCI NIH HHS P30 CA044579NCI NIH HHS R21 CA185955NCI NIH HHS R21 CA263381NCI NIH HHS R37 CA258829NIAMS NIH HHS R01 AR070234NIAMS NIH HHS R01 AR080436NIAMS NIH HHS R56 AR078686NIAMS NIH HHS T32 AR007098
Abstract
There is a need for better classification and understanding of tumor-infiltrating lymphocytes (TILs). Here, we applied advanced functional genomics to interrogate 9,000 human tumors and multiple single-cell sequencing sets using benchmarked T cell states, comprehensive T cell differentiation trajectories, human and mouse vaccine responses, and other human TILs. Compared with other T cell states, enrichment of T memory/resident memory programs was observed across solid tumors. Trajectory analysis of single-cell melanoma CD8
Indexed as
Lymphocytes, Tumor-InfiltratingMelanomaAnimalsCD8-Positive T-LymphocytesCell DifferentiationHumansMiceProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 ReceptorICBimmune checkpoint blockadeimmune persistencemelanomasurvivalsystems biologyT cell memoryTILstumor-infiltrating lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.